AOD-9604 is the tail end of growth hormone, residues 176 to 191, trimmed down to the fat-metabolism signal alone. It drives lipolysis and blocks lipogenesis through beta-3 adrenergic signaling while leaving IGF-1 and blood glucose untouched. That separation is the whole point of the molecule, and it is why the compound escapes the metabolic warnings attached to the GH class.
- Stimulates lipolysis and inhibits lipogenesis through beta-3 adrenergic signaling.PubMed: AOD-9604
- Keeps GH's fat-burning signal without raising IGF-1 or affecting glucose, the key distinction from GH-axis peptides.PubMed: AOD-9604
- Reported side effects are minimal, with no appetite, glucose, or IGF-1 signal.Peptide Guide, side-effect profile
- Potency in solution holds roughly 28 days by community estimate, with no published stability data behind it.r/Peptides community
- Straight talk: human efficacy data are modest, and the reference guide frames it as an adjunct rather than a standalone heavyweight.Peptide Guide, warnings